Therein, the mechanism by which MBTA vaccine therapy generates immunotherapeutic targets represents a unique vaccination strategy that is not directed at a single epitope, such as those targeted at mutated EGFR, rather it creates multiple tumor-specific targets by allowing the innate immune system and APCs to select for antigenic targets through endogenous processing and signaling cascades. The gene discussed is EGFR; the disease is neoplasm.